Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: Further test of the motivational salience hypothesis by Feng, Min et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Faculty Publications, Department of Psychology Psychology, Department of
2013
Avoidance disruptive effect of clozapine and
olanzapine is potentiated by increasing the test
trials: Further test of the motivational salience
hypothesis
Min Feng
Chinese Academy of Sciences, Beijing
Nan Sui
Chinese Academy of Sciences, Beijing, suin@psych.ac.cn
Ming Li
University of Nebraska-Lincoln, mli2@unl.edu
Follow this and additional works at: http://digitalcommons.unl.edu/psychfacpub
Part of the Chemicals and Drugs Commons, Pharmacy and Pharmaceutical Sciences Commons,
and the Psychology Commons
This Article is brought to you for free and open access by the Psychology, Department of at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Faculty Publications, Department of Psychology by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Feng, Min; Sui, Nan; and Li, Ming, "Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials:
Further test of the motivational salience hypothesis" (2013). Faculty Publications, Department of Psychology. 698.
http://digitalcommons.unl.edu/psychfacpub/698
Avoidance disruptive effect of clozapine and olanzapine is
potentiated by increasing the test trials: Further test of the
motivational salience hypothesis
Min Feng1,2,3, Nan Sui1,*, and Ming Li2,*
1Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences,
Beijing, China
2Department of Psychology, University of Nebraska-Lincoln, Lincoln, Nebraska, USA
3Graduate School of Chinese Academy of Sciences, Beijing, China
Abstract
Antipsychotic drugs suppress animals’ ability to avoid an aversive stimulus in the conditioned
avoidance response model (CAR). This behavioral effect is thought to reflect antipsychotic
activity and is suggested to be mediated by a drug’s action in attenuating the motivational salience
of a conditioned stimulus (CS). In the present study, we tested whether atypical antipsychotic
drugs clozapine and olanzapine act through this behavioral mechanism by manipulating the
number of avoidance test trials. We reasoned that more CS trials in the present of clozapine or
olanzapine would afford the drug more opportunities to decrease the motivational salience of the
CS, thus avoidance decline would be greater with the increase of CS trials in each test session. In
two separate experiments, adult male Sprague-Dawley rats were tested under clozapine (5.0 mg/
kg, sc), olanzapine (0.5 mg/kg, sc) or vehicle (sterile water) for 6 consecutive days in three CS
trial conditions (i.e. 3, 10, and 40 CS trials per session). Two days later, all rats were tested under
the same 40-trial session after receiving clozapine (5.0 mg/kg, sc) or olanzapine (0.5 mg/kg, sc).
Results show that repeated clozapine and olanzapine treatment persistently decreased avoidance
response, and this effect was potentiated by the increase of number of CS trials in the test sessions,
as the clozapine-treated or olanzapine-treated rats tested under the 40-trial or 10-trial condition
had significantly lower avoidance and faster decline across-sessions than those tested under the 3-
trial condition. This potentiated effect was not only seen in the total avoidance percentage, but also
observed in the within-session decline pattern in the last three drug test sessions and in the final
40-trial test session. These findings suggest that the clinical efficacy of a drug can be enhanced by
increasing the exposure of symptoms in the presence of the drug.
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1. Introduction
Antipsychotic drugs (APDs), including typical (e.g. haloperidol, HAL) and atypical (e.g.
clozapine, CLZ, and olanzapine, OLZ) classes, are effective in the treatment of psychotic
symptoms (e.g. delusions, hallucinations). Research over the years has shown that actions at
various receptor sites, notably dopamine D2, serotonin 5-HT2A, and/or 5-HT1A receptors,
are critically important for the therapeutic effect of antipsychotic drugs (Miyamoto et al.,
2005). How they work at the behavioral level is not entirely clear. One idea is that
antipsychotic treatment halts incentive learning and decreases aberrantly heightened
motivational salience of stimuli (e.g. psychotic thoughts, abnormal perceptions) which
typically grab a patient’s attention and instigate a motivated response (Kapur et al., 2005).
As a result, new aberrant beliefs are less likely to form and previously formed aberrant
memories are more likely to be extinguished (Beninger, 2006, Kapur, 2003, Kapur, Mizrahi,
2005, Miller, 1987). Clinical evidence that patients under drug treatment are less likely to
generate “erroneous” associations in the forms of delusions or hallucinations, and are less
bothered by their symptoms is consistent with this idea (Kapur et al., 2006, Mizrahi et al.,
2006). However, the precise treatment parameters and conditions (e.g. classes of drug, drug
dose, dosing regimens, routes of administration, environmental settings, with or without
psychotherapies, etc) that may modulate this putative action of antipsychotic drugs are not
well understood due to the complexity and heterogeneity of clinical conditions (Kapur,
2003, Kapur, Mizrahi, 2005, Mizrahi, Kiang, 2006, Remington and Kapur, 2010).
In recent years, we have used the conditioned avoidance responding (CAR) model and
examined the motivational salience attenuation action of APDs (Li et al., 2007). The CAR
model is a commonly used preclinical test for antipsychotic drugs with the suppression of
avoidance response as a behavioral index of antipsychotic activity (Li, Fletcher, 2007,
Porsolt et al., 2010). It is also an instrumental incentive (negative) conditioning paradigm
(Bolles and Grossen, 1970) which allows us to examine the role of motivational salience in
psychotic-like behavior in animals (Li et al., 2008) and investigate the motivational salience
attenuation action of APDs (Li et al., 2009, Zhang et al., 2011). In the CAR, a neutral
stimulus (e.g. white noise) is presented in close temporal contiguity with a foot-shock
(unconditioned stimulus, US), thus acquiring the motivational property of the US through an
incentive salience attribution process and becoming a conditioned stimulus (CS). As a CS, it
can instigate the motor response that is usually elicited by the US. One interesting finding on
the motivational salience attenuation action of APDs comes from our recent study in which
we tested three groups of rats under the same dose of HAL treatment (0.025 mg/kg, sc) but
under three different CS trial conditions (3, 10, 40 CS trials) for 6 days (Li, Fletcher, 2007).
We found that HAL-treated rats tested under the 40-trial test sessions showed a faster
decline than those tested under the 10-trial and 3-trial sessions across the 6 days of testing.
Two days later, when all groups were tested again in a 40-trial session after injected with
HAL 0.025 mg/kg, the 40-trial HAL had significantly lower avoidance responding than the
3-trial group (p=0.037, one-tail). These findings suggest that the more exposures to the CS
in the presence of HAL afford the drug more opportunities to decrease the motivational
salience of the CS and lead to a faster decline in avoidance responding - a position
compatible with the motivational salience attenuation hypothesis and also consistent with
our other findings showing that rats previously treated with HAL and CLZ still show
significantly lower avoidance responses even in the absence of drug (Li et al., 2004) and
risperidone and OLZ have a stronger suppressive effect on a less salient CS2-elicited
avoidance than a highly salient CS1-elicited avoidance (Li, He, 2009, Zhang, Fang, 2011).
The present study was designed to provide an additional test of the motivational salience
attenuation action of APDs using the different CS trial testing paradigm (Li, Fletcher, 2007).
If the avoidance disruptive effect of atypical drugs such as CLZ and OLZ is also modulated
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by the number of CS trials, with more trials in each test session leading to more disruption,
similar to what we have observed with HAL, it would provide strong support for the
motivational salience attenuation hypothesis.
2. Materials and Methods
2.1 Animals
Adult male Sprague-Dawley rats (226–250 g upon arrival, Charles River, Portage, MI) were
used. They were housed two per cage, in 48.3 cm × 26.7 cm × 20.3 cm transparent
polycarbonate cages under 12-hr light/dark conditions (light on between 6:30 am and 6:30
pm). Room temperature was maintained at 22±1°C with a relative humidity of 45–60%.
Food and water was available ad libitum. Animals were allowed at least one week of
habituation to the animal facility before being used in experiments. All procedures were
approved by the Institutional Animal Care and Use Committee at the University of
Nebraska-Lincoln.
2.2 Drugs
CLZ and OLZ (gifts from the NIMH drug supply program) were dissolved in 1.0% glacial
acetic acid in sterile distilled water (Kapur et al., 2003). All drugs were administrated
subcutaneously (sc), 1 h before testing in a volume of 1.0 ml/kg body weight. We tested
CLZ at 5.0 mg/kg in the first experiment and OLZ at 0.5 mg/kg in the second experiment.
These doses were chosen based on the following considerations: (1) our pilot work and
previous reports show that at these doses, CLZ and OLZ produce a reliable and comparable
disruption on avoidance responding (Mead and Li, 2009, Zhang and Li, 2012); (2) both CLZ
and OLZ at these doses also give rise to a clinically comparable range (40%–60%) striatal
dopamine D2 occupancy in rats (Kapur, VanderSpek, 2003, Wadenberg et al., 2001).
2.3 Two-way avoidance conditioning apparatus
Eight identical two-way shuttle boxes custom designed and manufactured by Med
Associates (St. Albans, VT) were used. Each box was housed in a ventilated, sound-
insulated isolation cubicle (96.52 cm W × 35.56 cm D × 63.5 cm H). Each box was 64 cm
long, 30 cm high (from grid floor), and 24 cm wide, and was divided into two equal-sized
compartments by a partition with an arch style doorway (15 cm high × 9 cm wide at base). A
barrier (4 cm high) was placed between the two compartments, so the rats had to jump from
one compartment to the other. The grid floor consisted of 40 stainless-steel rods with a
diameter of 0.48 cm, spaced 1.6 cm apart center to center, through which a scrambled
footshock (US, 0.8 mA, maximum duration: 5 s) was delivered by a constant current shock
generator (Model ENV-410B) and scrambler (Model ENV-412). The rat location and
crossings between compartments were monitored by a set of 16 photobeams (ENV-256-8P)
affixed at the bottom of the box (3.5 cm above the grid floor). Illumination was provided by
two houselights mounted at the top of each compartment. The CS (i.e. 76 dB white noise)
was produced by a speaker (ENV 224 AMX) mounted on the ceiling of the cubicle, centered
above the shuttle box. Background noise (approximately 74 dB) was provided by a
ventilation fan affixed at the top corner of each isolation cubicle. All training and testing
procedures were controlled by Med Associates programs running on a computer.
2.4 Experiment
2.4.1 Experiment 1: Effects of CLZ treatment on avoidance responding under
different CS trial conditions—This experiment examined the extent to which the
avoidance disruptive effect of CLZ is modulated by the number of CS trials. Sixty rats (in 2
batches) were first handled and habituated to the CAR boxes for 2 days (20 min/day). Then
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they were trained to acquire avoidance responding for 10 sessions (one/day) over a 2-week
period. Each session consisted of 30 trials, and each trial started with a presentation of a
white noise (CS) for 10 s, followed by a continuous scrambled footshock (0.8 mA, US,
maximum duration = 5 s) on the grid floor. If a rat moved from one compartment to the
other within the 10 s of CS presentation, it avoided the shock and this shuttling response was
recorded as avoidance. If the rat remained in the same compartment for more than 10 s and
made a crossing only after receiving the footshock, this response was recorded as escape. If
the rat did not switch compartments during the entire 5 s presentation of the shock, the trial
was terminated and escape failure was recorded. The total number of avoidance responses
was recorded for each session. Inter-trial intervals varied randomly between 30s and 60s.
One day after the last training session, rats were first tested under the CS-only condition (no
shock) to assess their baseline level of avoidance responding (40 trials of the CS
presentations). The CS-only condition was used to ensure that all rats had a consistent and
high level of CS-elicited avoidance response before the drug tests. Fifty rats that acquired a
robust and persistent avoidance response (≥ 28 avoidances in 40 trials) were matched and
randomly assigned to one of the following six groups based a 2 (CLZ vs. vehicle, VEH) × 3
(3, 10, 40 trials) between-subjects factorial design: CLZ 3-trial (n=8), VEH 3-trial (n=8),
CLZ 10-trial (n=8), VEH 10-trial (n=9), CLZ 40-trial (n=8) and VEH 40-trial (n=9). During
the next 6 consecutive days, the three CLZ groups were injected with the same dose of CLZ
(5.0 mg/kg, sc, −60 min) but tested under three different CS-only trial conditions (3, 10 or
40 CS presentations per session, no shock). The three VEH groups received the same VEH
(sterile distilled water, 1.0 ml/kg) treatment and tested under 3-trial, 10-trial or 40-trial
condition. Two days after the last (6th) drug test session, all rats were injected with the same
dose of CLZ (5.0 mg/kg, sc), and their avoidance behavior was tested in a CS-only 40-trial
session. This test was designed to further assess whether prior different trial test conditions
altered the motivational salience of the CS in the long run.
2.4.2 Experiment 2: Effects of OLZ treatment on avoidance responding under
different CS trial conditions—This experiment examined the extent to which the
avoidance disruptive effect of OLZ is modulated by the number of CS exposure in the
presence of the drug. The basic procedure was identical to that of Experiment 1 with the
exception that CLZ was replaced by OLZ (0.5 mg/kg). Sixty rats (in 2 batches) were initially
trained, of which 52 rats reached the training criterion and were used in the subsequent drug
tests. They were randomly assigned to one of six groups: OLZ 3-trial (n=9), VEH 3-trial
(n=8), OLZ 10-trial (n=8), VEH 10-trial (n=8), OLZ 40-trial (n=9), and VEH 40-trial (n=9)
groups and tested under OLZ (0.5 mg/kg, sc, −60 min) or VEH for 6 consecutive days. Two
days later, all rats were tested again in a CS-only 40-trial session 1 h after receiving 0.5 mg/
kg OLZ treatment.
2.5 Statistical Analysis
All data were expressed as mean ± S.E.M. Avoidance performance was expressed as the
percent avoidance (i.e. number of avoidance/total number of trials) or the absolute number
of avoidance responses and were analyzed using a split-plot analysis of variance (ANOVA)
with the between-subjects factors being treatment (CLZ or OLZ vs. VEH) and trial
conditions (3, 10, 40), and the within-subjects factor being test day (6 days). Group
differences on each specific test day were analyzed by one-way ANOVA followed by
Fisher’s LSD tests (>3 groups) or independent samples t tests (2 groups). Group differences
on the final 40-trial CS-only test were analyzed by one-way ANOVA followed by Fisher’s
LSD tests (>3 groups) or independent samples t tests (2 groups). A conventional two-tailed
level of significance at the 5% level was required. All data was analyzed using SPSS version
19.
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3. Results
3.1 Experiment 1: Effects of CLZ treatment on avoidance responding under different CS
trial conditions
3.1.1 Total avoidance percentage—Throughout the 6 days of testing, repeated CLZ
treatment disrupted avoidance responding persistently, primarily under the 10-trial and 40-
trial conditions. In addition, the 40-trial groups appeared to have lower avoidance than the
10-trial groups, which in turn, had lower avoidance than the 3-trial groups (Fig. 1A and B).
A split-plot ANOVA on the mean percent avoidance revealed a main effect of treatment [F
(1, 44) = 110.319, p < 0.001], a main effect of trial condition [F (2, 44) = 29.977, p < 0.001],
and a significant interaction between the two [F (2, 44) = 3.397, p = 0.042]. There was also a
main effect of test day [F (5, 220) = 3.655, p = 0.003] and a significant three-way interaction
among test day, treatment and trial condition [F (10, 220) = 2.063, p = 0.029], but no
significant test day × treatment interaction [F (5, 220) = 1.402, p = 0.225], nor test day ×
trial condition interaction [F (10, 220) = 1.177, p = 0.307].
To identify how the trial condition interacted with the CLZ treatment in decreasing
avoidance response, we analyzed avoidance percentage data under the CLZ and VEH
treatment separately. Under the CLZ treatment condition (Fig. 1A), a split-plot ANOVA
revealed a main effect of trial condition [F (2, 21) = 16.085, p < 0.001], but no main effect
of test day [F (5, 105) = 1.671, p = 0.148] or interaction between the two [F (10, 105) =
1.057, p = 0.402]. Post hoc LSD tests showed that the CLZ 40-trial and 10-trial groups had
significantly lower avoidance than the CLZ 3-trial group, ps ≤ 0.001. One-way ANOVAs
followed by post hoc LSD tests on each test day revealed that the CLZ 40-trial group had
significantly lower avoidance than the CLZ 3-trial group on all 6 days, all ps < 0.016. The
CLZ 10-trial group had significantly lower avoidance than the CLZ 3-trial group on day 1,
2, 5 and 6, all ps < 0.025, suggesting that the avoidance disruptive effect of CLZ was
enhanced by the increase of CS trials throughout the 6 days of testing.
Under the VEH treatment condition (Fig. 1B), there was a main effect of trial condition [F
(2, 23) = 16.482, p < 0.001], a main effect of test day [F (5, 115) = 6.203, p < 0.001], and a
significant interaction between the two [F (10, 115) = 4.107, p < 0.001]. Post hoc tests
showed that the VEH 40-trial group had significantly lower avoidance than the VEH 10-trial
and 3-trial groups, ps ≤ 0.001. One-way ANOVAs followed by post hoc tests on each test
day revealed that the VEH 40-trial group had significantly lower avoidance than the VEH 3-
trial group on all 6 days except on day 2, and than the VEH 10-trial group on the last 4 days,
ps < 0.05. The VEH 10-trial group had significantly lower avoidance than the VEH 3-trial
group on day 4 and day 6, ps < 0.05. Overall, both CLZ treatment and more CS trials caused
a decline in avoidance response throughout the 6 days of testing. The disruptive effect of
CLZ was further potentiated by the increase of CS trials.
3.1.2 Within-session pattern of avoidance response—If CLZ indeed decreased the
motivational salience of the CS, we would also expect to see a within-session decline in the
drug test sessions. To illustrate this point, we selectively examined the avoidance data in
each 10-trial block (a total of 4 blocks per session) on the last three drug test days from the
two 40-trial groups (Fig. 2). The within-session decline pattern was clearly observed. On
day 4, a split-plot ANOVA revealed a main effect of block [F (3, 45) = 8.494, p < 0.001], a
main effect of treatment [F (1, 15) = 40.341, p < 0.001], but no significant block × treatment
interaction [F (3, 45) = 0.503, p = 0.682]. In the CLZ 40-trial group, paired sample t tests
revealed that the block 2, 3 or 4 was significantly different from the block 1, all ps < 0.05. In
the VEH 40-trial group, the block 3 and 4 were also significantly different from the block 1,
all ps < 0.05.
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On day 5, the effects of block [F (3, 45) = 8.524, p < 0.001] and treatment [F (1, 15) =
36.190, p < 0.001] were significant, but their interaction was not [F (3, 45) = 1.688, p =
0.183]. Paired sample t tests revealed that the block 2 and 3 were significantly different from
the block 1 in the CLZ 40-trial and VEH 40-trial group, all ps < 0.05.
Similar to day 4 and 5, there was a main effect of block [F (3, 45) = 7.253, p < 0.001], a
main effect of treatment [F (1, 15) = 134.434, p < 0.001], but no significant block ×
treatment interaction [F (3, 45) = 0.174, p = 0.913] on day 6. Paired sample t tests revealed
that the block 2, 3 or 4 was significantly different from the block 1 in the CLZ 40-trial
group, all ps < 0.05. In the VEH 40-trial group, the block 2 and 3 were also significantly
different from the block 1, all ps < 0.05.
Two days later, all groups were tested again in a 40-trial session after injected with CLZ 5.0
mg/kg. There was no significant group difference among the three CLZ groups on the total
number of avoidances, F (2, 21) = 1.190, p = 0.324 (Fig. 3A), indicating that the 40- and 10-
trial conditions at this low dose of CLZ did not induce a long-lasting alteration of
motivational salience of the CS. Similarly, no group difference was noted among the three
VEH groups, F (2, 23) = 0.531, p = 0.595. However, the single administration of CLZ still
caused a within-session decline in avoidance responding across the four 10-trial test blocks
in both the CLZ-treated groups, F (3, 63) = 25.751, p < 0.001; and the VEH groups, F (3,
69) = 22.096, p < 0.001 (Fig. 3B), a behavioral response pattern similar to what was shown
during the repeated drug test phase.
3.2 Experiment 2: Effects of OLZ treatment on avoidance responding under the different
CS trial conditions
3.2.1 Total avoidance percentage—Throughout the 6 days of drug testing (Fig. 4),
repeated OLZ treatment progressively increased its disruption of avoidance response,
especially in the 10-trial and 40-trial condition. A split-plot ANOVA revealed a main effect
of treatment [F (1, 46) = 21.400, p < 0.001], a main effect of trial condition [F (2, 46) =
8.319, p = 0.001], a main effect of test day [F (5, 230) = 16.955, p < 0.001]. In addition,
there was a significant test day × treatment interaction [F (5, 230) = 7.006, p < 0.001] and a
significant test day × trial condition interaction [F (10, 230) = 3.016, p = 0.001], but no
significant treatment × trial condition interaction [F (2, 46) = 1.331, p = 0.274] nor test day
× treatment × trial condition three-way interaction [F (10, 230) = 1.049, p = 0.403]. Post hoc
tests indicated that the 40-trial condition had significantly lower avoidance responses than
the other two conditions, ps < 0.035. These analyses support the observation that OLZ
caused an across-session decline in avoidance response and avoidance performance declined
across sessions at different rates under the different trial conditions.
Next, we compared avoidance performance across the three different trial conditions under
either OLZ or VEH. First, under the OLZ treatment condition (Fig. 4A), a split-plot
ANOVA revealed a main effect of trial condition [F (2, 23) = 6.050, p = 0.008], a main
effect of test day [F (5, 115) = 15.949, p < 0.001], and a significant interaction between the
two [F (10, 115) = 2.172, p = 0.024]. Post hoc LSD tests showed that the OLZ 40-trial group
had significantly lower avoidance than the OLZ 3-trial group, p < 0.05. One-way ANOVAs
followed by post hoc LSD tests on each test day revealed that the OLZ 40-trial group had
significantly lower avoidances than the OLZ 3-trial group on all 6 days except on day 1 and
day 3, and than the OLZ 10-trial group on the last test day, ps < 0.05. The OLZ 10-trial
group had significantly lower avoidance than the OLZ 3-trial group on day 2 and day 6, ps <
0.05. This analysis suggests that the avoidance disruptive effect of OLZ was enhanced by
the increase of CS trials across the 6 days of testing.
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In contrast, under the VEH condition (Fig. 4B), there was no main effect of the trial
condition [F (2, 23) = 2.366, p = 0.116], no main effect of test day [F (5, 115) = 2.184, p =
0.061], and no significant interaction between the two [F (10, 115) = 1.688, p = 0.092],
suggesting that different number of CS trials did not significantly affect avoidance response
over time under the vehicle condition. Collectively, OLZ treatment caused a progressive
decline in avoidance response throughout the 6 days of testing, and this disruptive effect was
further potentiated by the increase of the CS test trials. Contrary to the results from
Experiment 1, the increase of CS trial numbers did not cause an increase in avoidance
decline under the vehicle treatment.
3.2.2 Within-session pattern of avoidance response—Analysis of the within-
session response pattern on the last three drug days revealed an apparent across-block
decline in the OLZ group (Fig. 5). On day 4, a split-plot ANOVA revealed a main effect of
block [F (3, 48) =7.529, p < 0.001], a main effect of treatment [F (1, 16) = 18.382, p =
0.001], but no significant block × treatment interaction [F (3, 48) = 0.969, p = 0.415]. Paired
sample t tests revealed that the block 3 and 4 were significantly different from the block 1 in
the OLZ 40-trial group, all ps < 0.05. No block difference was noted in the VEH 40-trial
group.
Similarly on day 5, there was a main effect of block [F (3, 48) = 4.880, p = 0.005], a main
effect of treatment [F (1, 16) = 17.891, p = 0.001], but no significant block × treatment
interaction [F (3, 48) = 0.148, p = 0.931]. Paired sample t tests showed that the block 2 was
significantly different from the block 1, p< 0.05 in the OLZ 40-trial group. No block
difference was noted in the VEH 40-trial group, ps > 0.112.
On day 6, there was also a main effect of block [F (3, 48) = 11.209, p < 0.001], a main effect
of treatment [F (1, 16) = 11.866, p = 0.003], but no significant block × treatment interaction
[F (3, 48) = 2.090, p = 0.114]. Paired sample t tests showed that the block 2, 3 and 4 were
significantly different from the block 1 in the OLZ 40-trial group, ps < 0.05, while in the
VEH 40-trial group, only the block 2 was significantly different from the block 1, ps < 0.05.
On the final 40-trial CS-only OLZ challenge test when all rats were injected with OLZ 0.5
mg/kg (Fig. 6), the three OLZ groups did not differ from each other on the total number of
avoidances, F (2, 23) = 0.539, p = 0.590 (Fig. 6A), again, indicating no long-lasting
alteration of motivational salience of the CS. Similarly, no group difference was noted
among the three VEH groups, F (2, 23) = 0.473, p = 0.629. Like CLZ, acute injection of
OLZ still caused a within-session decline across the four 10-trial test blocks in both the
OLZ-treated groups, F (3, 69) = 45.890, p < 0.001; and the VEH groups, F (3, 69) = 39.339,
p < 0.001 (Fig. 6B).
4. Discussion
The present study examined the effect of repeated CLZ and OLZ treatment on avoidance
responding under different CS trial conditions in an attempt to delineate the behavioral
mechanisms of action of CLZ and OLZ in the CAR model (e.g. motivational salience
attenuation). The rationale was that if CLZ and OLZ decrease avoidance response by
attenuating the motivational salience of the CS, increasing the number of CS trials in each
test session would enhance their disruptive effects given the fact that more CS trials afford
more opportunities for CLZ and OLZ to attenuate its salience. Our results are consistent
with this hypothesized action of antipsychotic drugs, although the findings from both
experiments may be subjected to alternative explanations (e.g. motor fatigue or state-
dependent learning, etc).
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In Experiment 1, we showed that repeated CLZ treatment persistently decreased avoidance
response, consistent with our previous finding (Li et al., 2010). More importantly, this CLZ
effect was potentiated by the increase of number of CS trials in the test sessions, as the CLZ-
treated rats tested under the 40-trial and 10-trial conditions had significantly lower
avoidance than those tested under the 3-trial condition throughout the six days of testing.
This potentiated effect was not only seen in the total avoidance percentage, but also reflected
in the within-session decline pattern, which is typically regarded as the consequence of
extinction of motivational salience (Wise, 2004, Wise et al., 1978). These findings suggest
that CLZ may have attenuated the ability of the CS to instigate avoidance response (i.e. its
motivation salience). Interestingly, the CS trial condition itself also had an extinction-like
effect on avoidance response, with more CS trials causing a faster across-session decline.
Thus the potentiated effect between CLZ and CS trials can also be viewed as CLZ
facilitating the extinction of avoidance response, a finding consistent with previous reports
with chlorpromazine (Miller et al., 1957) as well as HAL and CLZ (Li, Parkes, 2004).
In Experiment 2, we observed that repeated OLZ treatment progressively enhanced its
disruption of avoidance response, a finding consistent with our previous work (Li, Fletcher,
2007, Li, He, 2009, Li et al., 2012, Li, Sun, 2010, Mead and Li, 2010, Zhang, Fang, 2011,
Zhang and Li, 2012). Similar to that of CLZ, this effect was also enhanced by the increase of
number of CS trials, as OLZ-treated rats tested under the 40-trial condition had a faster
decline than those tested under the 10- or 3-trial condition (Fig. 4A). This potentiation by the
CS trials was also seen in the with-session decline pattern on the last three drug days as well
as in the final challenge test in both OLZ- and vehicle-treated rats. As a within-session
decline has often been used as evidence supporting the reinforcement attenuation effect of
drugs (Dickinson et al., 2000, Fouriezos et al., 1978), the fact of both CLZ and OLZ caused
this pattern of response change indicates that the CS was gradually losing its motivational
ability under the influence of CLZ and OLZ.
One alternative explanation on the within-session decline is the motor fatigue. It was
possible that rats tested under the 40-trial condition became fatigued as the trials progressed.
This explanation is not supported by the following two observations. First, the VEH 40-trial
rats in both experiments made no fewer avoidance responses (often more) in the 4th block
than in the 2nd and 3rd blocks (Figures 3 and 6). Second, the VEH 40-trial rats in Experiment
2 did not make significantly lower avoidance than the VEH 10-trial or VEH 3-trial rats. If
motor fatigue was the cause of the within-session decline, we would expect to see lower
avoidance in the 4th block than in other blocks and lower avoidance in the 40-trial group
than in other groups, opposite to the ones presented above. Another alternative relates to the
state-dependent learning (Overton, 1979). That is, rats may have adapted to a learning state
consisting of an association between a drug’s effects and avoidance behavior in the CAR.
Thus, an increase in the trial numbers may lead to an increase of the number of occasions to
strengthen this association, resulting in an increase in the inhibition of avoidance responding
under a more trials condition. This alternative explanation needs to be carefully examined in
the future study.
One unexpected discrepancy between Experiment 1 and 2 was the avoidance performance in
the VEH groups. In Experiment 1, the VEH 40-trial group had significantly lower avoidance
than the VEH 10-trial and 3-trial groups, whereas no such group difference was found in
Experiment 2. We do not have a solid explanation for this difference. One possibility is the
batch difference and time of experiment as the two experiments consisting of four batches of
rats were conducted at different times of the year. As a piece of supporting evidence, we did
notice that rats in Experiment 1 had a significantly higher baseline level of avoidance
response than those in Experiment 2: the mean avoidance percentage at the baseline in
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Experiment 1 was 93.76%, while it was 97.13% in Experiment 2 (Independent sample t test,
t (101) = 2.488, p = 0.014, 2-tailed).
The overall finding from the present study is consistent with our previous work on the
motivational salience attenuation action of APDs (Li, Fletcher, 2007, Li, He, 2009, Zhang,
Fang, 2011) as well as others (Beninger et al., 1980a, 1980b, Davis et al., 1961). Davis et al.
(1961) first trained rats to escape footshock in the shuttle box, then confined them in one
side of the box and exposed them to 15 trials of the buzzer-footshock pairing under either
chlorpromazine or saline. When tested without drug, the previously chlorpromazine-treated
rats made significantly fewer avoidance responses than the saline rats, demonstrating that it
was the action of chlorpromazine on the motivational salience of the buzzer that contributed
to the lower avoidance in the chlorpromazine-treated rats. Beninger et al. (1980a, b) showed
that avoidance responding under pimozide showed an extinction-like gradual decline with
repeated drug testing. We have shown that HAL treatment also caused a within-session
decline in avoidance responding (Li, Fletcher, 2007); and CLZ, OLZ and risperidone disrupt
avoidance response elicited by a less salient conditioned stimulus (CS2) to a greater extent
than avoidance elicited by a more salient stimulus (CS1) (Li, He, 2009, Li, Sun, 2012,
Zhang, Fang, 2011). Clearly, these observations, together with the present ones, suggest that
the motivational salience attenuation action of APDs is perhaps the critical action of APDs
on avoidance.
Although the main finding that the avoidance disruptive effect of CLZ and OLZ was
potentiated by the increase of number of CS test trials is consistent with the motivational
salience attenuation hypothesis, it could also be viewed as a phenomenon of the “rate-
dependent drug effects” (Barrett and Bergman, 2008, Leander, 1975, Leander and
McMillan, 1974). It is well known that the baseline response rate is an important
determinant of the behavioral effects of drugs. A drug’s behavioral effect and the direction
of its effect can be quite different under different test conditions (Barrett, 2002, Barrett and
Bergman, 2008, Dews, 1976, McMillan and Katz, 2002, Spealman et al., 1983). Therefore,
the different drug trial groups (e.g. 3, 10 or 40 trials) may have shown different avoidance
decline rates because of their different baseline avoidance numbers, in addition to the
salience attenuation action of APDs. Based on our recent study showing that the baseline
rate of avoidance responses does not influence the basic avoidance-disruptive effect of OLZ
and risperidone (another antipsychotic drug) (Zhang, Fang, 2011), we speculate that the
motivational salience attenuation action is a more plausible cause. Other reports in the
literature also find that the effects of some antipsychotic drugs, such as thioridazine,
chlorpromazine and haloperidol can be largely independent of the type of schedule or the
type of consequent event that maintains response (Spealman, Kelleher, 1983, Wenger,
1979).
CLZ and OLZ possess a much more potent antagonism on the 5-HT2A/2C receptors in
addition to relatively weak antagonism on D2 receptors (Meltzer et al., 2003). It is thus
possible that their disruptive effect on CAR could be attributed to their action on D2
receptors alone (Kapur and Seeman, 2001, Wadenberg, Soliman, 2001) or its dual action on
both 5-HT2A/2C and D2 receptors (Meltzer et al., 1989) or even effects on other receptors
(e.g. D1, D4, 5-HT1A). Our recent work indicates that CLZ disrupts avoidance response
primarily by blocking 5-HT2A/2C receptors, whereas OLZ appears to exert its disruptive
effect primarily by blocking dopamine D2 receptors (Li, Sun, 2012, Li, Sun, 2010). We
found that pretreatment of 1–2, 5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-
HT2A/2C agonist, 2.5 mg/kg, sc), but not quinpirole (a selective dopamine D2/3 agonist, 1.0
mg/kg, sc), attenuated CLZ-induced disruption of avoidance responding, whereas
pretreatment of quinpirole, but not DOI, attenuated that effect of OLZ. In light of the present
findings, we suggest that CLZ may attenuate motivational salience of the CS by blocking 5-
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HT2A receptors, which in turn decreases dopamine release (Ichikawa et al., 2001, Millan et
al., 1998). OLZ may decrease motivational salience of the CS by directly blocking
dopamine D2 receptors as D2 blockade is known to decrease motivational salience of stimuli
in the control of behavior (Berridge, 2007).
In conclusion, the present study provides support for the motivational salience attenuation
action of OLZ and CLZ in the CAR model by showing that their avoidance disruptive effect
can be potentiated by increasing the number of CS trials. It is clinically relevant as the
experimental approach described in this study could be potentially used to examine the
interactive effects of psychotherapy (e.g. exposure therapy) and pharmacotherapy (e.g.
antipsychotic treatment) and associated mechanisms at the behavioral and brain levels. If our
findings were any indication of such an interaction in the treatment of psychosis (avoidance
as a proxy), it appears that combined treatment would yield an optimal result.
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Highlights
• Repeated clozapine and olanzapine treatment persistently decreased avoidance
response in rats.
• Their avoidance disruptive effect was potentiated by the increase of number of
test trials.
• The potentiation was observed also in the within-session decline of avoidance
responding pattern.
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Figure 1.
Percentage of avoidance response (Mean + S.E.M) made by rats treated with CLZ 5.0 mg/kg
(A) or vehicle (VEH) (B) and tested under the 3 CS trial conditions (3, 10, or 40 trials/day)
on the pre-drug day and throughout the 6 test days. *p < 0.05, **p < 0.001 in comparison to
the respective 3-trial group, #p < 0.05, ##p < 0.001 in comparison to the respective 10-trial
group.
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Figure 2.
Number of avoidance responses across the four 10-trial blocks made by rats treated with
CLZ 5.0 mg/kg (A) or vehicle (VEH) (B) and tested under the 40 trial condition on the last 3
test days. *p < 0.05 in comparison to the respective block 1.
Feng et al. Page 15
Pharmacol Biochem Behav. Author manuscript; available in PMC 2014 January 01.
$watermark-text
$watermark-text
$watermark-text
Figure 3.
(A) Total number of avoidance responses and (B) number of avoidances across the four 10-
trial blocks made by rats on the final 40 trial CS-only test in which all rats were treated with
CLZ 5.0 mg/kg. #p < 0.050 indicates a significant effect of block.
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Figure 4.
Percentage of avoidance response (Mean + S.E.M) made by rats treated with olanzapine
(OLZ) 0.5 mg/kg (A) or vehicle (VEH) (B) and tested under the 3 CS trial conditions (3, 10,
or 40 trials/day) on the pre-drug day and throughout the 6 test days. *P < 0.05, **P < 0.001
in comparison to the respective 3-trial group, #P < 0.05 in comparison to the respective 10-
trial group.
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Figure 5.
Number of avoidance responses across the 4 10-trial blocks made by rats treated with
clozapine (CLZ) 5.0 mg/kg (A) or vehicle (VEH) (B) and tested under the 40 trial condition
on the last 3 test days. *P < 0.05 in comparison to the respective block 1.
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Figure 6.
(A) Total number of avoidance responses and (B) number of avoidances across the four 10-
trial blocks made by rats on the final 40 trial CS-only test in which all rats were treated with
OLZ 0.5 mg/kg. #p < 0.050 indicates a significant effect of block.
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